
Dr. Wang Presented Study Results of New Wet AMD Treatment Approach at the ARVO 2025 Meeting
On May 9, 2025, Texas Retina’s Robert C. Wang, MD, presented “Top Line Results from ODYSSEY: A Phase IIb Study of Suprachoroidally Administered CLS-AX in Participants with Neovascular Age-related Macular Degeneration” at
read more
Dr. Anand Participated in Research on New Gene Therapy Drug for X-linked Retinitis Pigmentosa Published in American Journal of Ophthalmology
The two-year results of the Phase I/II, multi-center HORIZON clinical trial of the new subretinal gene therapy drug AGTC-501 for X-linked retinitis pigmentosa were recently published in the American Journal of Ophthalmology.
read more
Dr. Anand Presented Interim Study Results of New Gene Therapy for X-linked Retinitis Pigmentosa at ASRS 2024 Annual Meeting
Texas Retina’s Rajiv Anand, MD, presented “Subretinal AGTC-501 Gene Therapy for XLRP: 12-Month Interim Safety & Efficacy Results of the Randomized Controlled Multicenter Phase II Skyline Trial” at the 2024 Annual Meeting
read more
Kimberly Jones Recognized for 26+ Years of Service to Texas Retina
We are continuing to celebrate our team members who have been a part of the Texas Retina family for 20 years or more. Today we recognize Kimberly Jones who joined our team
read more
Honoring Our Physicians
Tomorrow, March 30, is National Doctor’s Day. At Texas Retina, we celebrate all 16 of our physicians as well as all of the physicians who care for our patients and communities. Thank
read more